Benign prostatic hyperplasia
Conditions
Interventions
To examine efficacy and safety of switch from Silodosin to 0.2 mg Tamsulosin. (12weeks)
Sponsors
Hokkaido University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. male patients aged 50 or older 2. patients treated with Silodosin 8mg for over 8 weeks 3. question number 3 of QOL score: 3 points or more 4. patients with lower urinary tract symptoms (IPSS: 8 points or more, QOL score 3 points or more) 5. patients who want to change from Silodosin to Tamsulosin 6. patients with informed consent
Exclusion criteria
Exclusion criteria: 1. patients treated with other alpha 1 blocker 2. patients Tamsulosin is contraindicated 3. patients treated with anti cholonergic agents 4. patients treated with anti androgen agents 5. patients treated with drug could change urination 6. patients with prostate cancer 7. patients with the history of TUR-P 8. patients with the history of hyperthermia for benign prostatic hyperplasia 9. patients with neurogenic bladder 10. patients with urethral stricture 11. patients with using self catheterization 12. patients with the history of radiation therapy 13. patients with active urinary infection 14. patients who have been determined to be unsuitable as a subject by a physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom score | — |
Countries
Japan
Contacts
Public ContactTakahiko Mitsui
Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery
Outcome results
None listed